Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Notice of results and shareholder update

14th Mar 2012 09:23

RNS Number : 3183Z
Allergy Therapeutics PLC
14 March 2012
 



Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

14 March 2012

 

 

Notice of results and shareholder update

 

 

Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines will announce its interim results for the period ended 31 December 2011 on 30 March 2012.

 

 

The Company also announces that CFR Pharmaceutical SA ("CFR"), a company associated with the Weinstein family and the largest shareholder in Allergy Therapeutics, will today release its annual report for the year ended 31 December 2011. In order that CFR can comply with its reporting requirements Allergy Therapeutics has made the following unaudited financial information below available to CFR.

 

Balance Sheet as at 30 September 2011

 

 

£ '000

Total Non Current Assets

 17,969

Total Current Assets

 15,229

Total Current Liabilities

(10,162)

Total Non Current Liabilities

(20,328)

Total Equity

2,708

 

Consolidated Income Statement for the 12 months ended 30 September 2011

 

£'000

Revenue

42,156

(Loss) for the period

(1,028)

 

Items have the same meaning as disclosed in Allergy Therapeutics plc's accounts for the year ended 30 June 2011.

 

 

-Ends-

 

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite, Finance Director

www.allergytherapeutics.com

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Clare Terlouw

FTI Consulting

+44 (0) 207 831 3113

Simon Conway/ Susan Quigley

 

 

 

Notes to editors

 

 

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORJIMLTMBBBMAT

Related Shares:

Allergy Thera.
FTSE 100 Latest
Value8,596.28
Change53.72